ENA Respiratory is developing its first-in-class, broad-spectrum antiviral nasal spray — known as INNA-051 — for populations at risk of developing complications from respiratory viral infections, including COVID-19. Now, the Australian company is teaming up with the COPD Foundation, a nonprofit with a mission to improve the…
Respira Labs has raised $2.8 million to help develop a wearable device that uses sound to evaluate lung function in people with respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and COVID-19. “We’re a U.S.-based startup excited to be making strides in a highly competitive space…
The U.S. Food and Drug Administration (FDA) has given final approval to Zydus Pharmaceuticals to start marketing roflumilast tablets at a dose of 500 micrograms (mcg), according to a company press release. Roflumilast tablets are a generic version of oral Daliresp, manufactured by AstraZeneca. Like the brand-name medicine,…
The U.S. Food and Drug Administration (FDA) has approved Lupin Limited’s generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). Like the name-brand medicine sold by Sunovion Pharmaceuticals, the new generic is indicated for long-term maintenance treatment, according to…
A Phase 2 trial designed to test a self-administered inhaled formulation of nitric oxide (NO) for adults with chronic obstructive pulmonary disease (COPD), or bronchiectasis, is recruiting eligible patients. The formulation, called RESP301, is a liquid solution that, once inhaled through a nebulizer, releases NO into the lungs. RESP301 was…
Abnormally high levels of iron inside airway immune cells are associated with more frequent lung infection-related exacerbations in people with chronic obstructive pulmonary disease (COPD), a study shows. Excess iron was also shown to impair the ability of these cells, called macrophages, to fight COPD-related microbes, and can be used…
A team of researchers have created a comprehensive blueprint of cells that are in the lungs of chronic obstructive pulmonary disease (COPD) patients, which helped them identify previously unknown cell subpopulations and changes in gene activity and cellular interactions. “Our analysis identified novel changes in gene expression [activity] and…
Animal and human studies highlight the potential of nomacopan, an investigational inhaled medicine to alleviate severe exacerbations caused by inflammatory lung diseases, such as chronic obstructive pulmonary disease (COPD). Akari Therapeutics, the company developing the therapy, is collaborating with Inhalation Sciences to refine the dosing and pharmacological…
Verona Pharma has completed patient enrollment for ENHANCE-2, a Phase 3 clinical trial evaluating the safety and efficacy of ensifentrine, an inhalation therapy for chronic obstructive pulmonary disease (COPD). According to Verona, the trial exceeded its enrollment target of 800 participants, even amid the COVID-19 pandemic. Top-line data are…
Researchers have discovered that an ion channel protein called TRPML3 may be a new therapeutic target for chronic obstructive pulmonary disease (COPD). Their preclinical study found that the protein regulates the levels of MMP-12, a molecule produced in lung immune cells and known to drive COPD. Mice lacking the…
Get regular updates to your inbox.